The Filing Desk

DBV Technologies

DBVT · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

DBVT · Last close · November 19, 2026
$9.42
Value DBV Technologies yourself

DBV Technologies' revenue rose 35.8% to $6 million in fiscal 2025. Its operating margin was −2,609.2%, up from −2,808.7% a year earlier. Free cash flow was −$122 million. The diluted share count rose 43.9%.

DBV TECHNOLOGIES S.A. Latest fiscal year ended December 31, 2025 10-K filed March 26, 2026 · 0001628280-26-021504 Updated
Revenue
$6M
35.8%
Operating margin
−2,609.2%
199.5 pts
Net income
−$147M
 
Free cash flow
−$122M
 
Return on equity
−149.8%
13.9 pts
Market cap
$4.2B
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What DBV Technologies does

DBV Technologies is a French drug developer working on treatments for food allergies in children. Its product, Viaskin, is a skin patch that carries a tiny dose of an allergen, such as peanut protein. The idea, called epicutaneous immunotherapy, is that cells in the skin carry the allergen to the immune system and slowly make the child less sensitive to it, without the allergen entering the bloodstream.

It has no approved products and no sales yet. Its main candidate, the Viaskin Peanut Patch, has been tested in twelve completed clinical trials. In its annual report the company said it planned to ask the US Food and Drug Administration for approval for children aged four to seven in the first half of 2026, and for toddlers aged one to three later in 2026 if a safety study succeeds. It also has earlier-stage work on a milk allergy patch. It names oral treatments for peanut allergy, such as Palforzia, and the antibody drug Xolair among other treatments.

DBV lost $146.9 million in 2025 and had $194.2 million in cash at the end of the year, before raising more from warrant exercises. Its headquarters are in Châtillon, France, and its main US office is in Warren, New Jersey. It had 125 full-time employees at the end of 2025.

Its biggest risks, as it describes them

  • It depends almost entirely on its Viaskin patch, which may never win approval or sell well.
  • Regulators in the United States or Europe may refuse or delay approval of its peanut patch.
  • Continuing losses, and the need to raise more money that may not be available on good terms.
  • Its reliance on outside manufacturers and suppliers, and the challenge of making patches at large scale.
  • French law limits how easily it can issue new shares to raise capital.
From DBV Technologies's annual report on Form 10-K, filed March 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both. Where the filings' structured data doesn't give a year's net income, the column is blank.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

DBV Technologies lost money in fiscal 2025: a net loss of $147 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments7720914132194
Debt incl. finance leases0————
Net debt (negative means net cash)−77————
Net debt to EBITDA—————
Debt to equity0.0x————
Interest coverage—————
Current ratio3.6x7.6x4.3x1.4x3.7x
Quick ratio3.6x7.6x4.3x1.4x3.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, billions

Projections

Project DBV Technologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought DBV Technologies shares on the open market, and 2 insiders sold $15.5 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 29, 2026Pharis MohideenChief Medical OfficerSold464$2.70$1,253Form 4
Jan 29, 2026Pharis MohideenChief Medical OfficerSold534$4.86$2,595Form 4
Dec 18, 2025Bpifrance EPICMember of 10% owner groupSold1,292,103$4.19$5.4 millionForm 4
Dec 17, 2025Bpifrance EPICMember of 10% owner groupSold2,076,990$4.85$10.1 millionForm 4
Nov 21, 2025Pharis MohideenChief Medical OfficerSold1,624$2.77$4,498Form 4
Nov 20, 2025Pharis MohideenChief Medical OfficerSold6,496$2.88$18,708Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−286.1%−2,646.8%−2,123.8%
Altman Z''0.74−24.08−2.64
Accruals ratio71.0%−7.6%−17.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put DBV Technologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
DBV TechnologiesFY2535.8%−2,609.2%−2,159.6%———
Abeona TherapeuticsFY25—−1,536.9%−1,448.5%———Compare
CerenomeFY25−10.5%−293.5%−399.8%———Compare
Korro BioFY25181.5%−1,906.4%−1,237.2%———Compare
X4 PharmaceuticalsFY25150.0%−1,336.7%−1,317.2%——3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue———1511651646
Revenue growth————−23.3%−49.4%−15.1%224.7%−73.6%35.8%
Gross profit——————————
Research and development———11510270766089117
Operating income———−171−159−99−97−76−117−147
Net income———−172−160−989673−114−147
Diluted EPS (US$)———−4.65−2.95−1.78−1.24−0.76−1.17−1.05
Diluted shares (millions)2424,75728,925375455779597140
Cash flow
Cash from operations———−148−166−108−56−80−104−121
Capital expenditure———6311120
Free cash flow———−154−168−109−56−80−107−122
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation———17−135655
Balance sheet at fiscal year end
Cash and short-term investments——1411931967720914132194
Debt incl. finance leases——3210————
Total assets———27227214724618366234
Total liabilities———78674752433865
Shareholders' equity——1391932069919414027169
Margins and ratios
Gross margin——————————
Operating margin———−1,162.8%−1,408.7%−1,727.7%−1,994.9%−486.0%−2,808.7%−2,609.2%
Net margin———−1,169.5%−1,415.0%−1,713.5%1,987.5%462.3%−2,744.3%−2,607.3%
Free cash flow margin———−1,046.5%−1,493.4%−1,912.3%−1,164.7%−510.8%−2,573.2%−2,159.6%
Rule of 40 (growth + FCF margin)————−1,516.7%−1,961.6%−1,179.9%−286.1%−2,646.8%−2,123.8%
Return on capital——————————
Return on equity————−80.0%−64.2%65.5%43.5%−136.0%−149.8%
Return on assets————−58.7%−46.7%49.0%33.9%−91.6%−98.2%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: DBV Technologies' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with DBV Technologies.